Details der Publikation - The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors

The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors

Introduction Immune checkpoint inhibitors (ICIs) became the standard of care for several solid tumors. A limited fraction of patients (pts) achieves a long-term benefit. Plasmatic and intracellular cholesterol levels have emerged as promising biomarkers. The aim of the present study was to determine whether cholesterol efflux capacity (CEC), mediated by serum transporters (ABCA1 and ABCG1) and passive diffusion (PD), impacts on clinical outcome of advanced non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) pts treated with ICIs. Material and methods We retrospectively enrolled advanced NSCLC and mRCC pts consecutively treated with ICIs between October 2013 and October 2018. CEC and cholesterol loading capacity (CLC) were assessed by well-established specific cell models. As primary endpoint, CEC, PD and CLC were correlated with overall survival (OS) while the effects of these parameters on progression-free survival (PFS) and clinical benefit (CB), defined as complete/partial response or stable disease, represented secondary endpoints. Results NSCLC accounted for 94.2% of 70 enrolled cases, and serum sample suitable for CEC and PD determination was available in 68. Blood cholesterol and serum ABCA1, ABCG1, PD and CLC were associated with outcomes (OS, PFS and CB) at univariate analysis. At the multivariate analysis, only PD confirmed its positive prognostic value in terms of OS, PFS and CB. Conclusion The favorable impact of cholesterol PD on clinical outcome might reflect its main conformation in mature HDL particles which potentially shape an inflamed context, ultimately promoting ICI efficacy. Further prospective studies are needed to support our findings and uncover targetable pathways..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:72
Enthalten in:	Cancer immunology immunotherapy - 72(2023), 7 vom: 24. Feb., Seite 2127-2135

Sprache:	Englisch

Beteiligte Personen:	Perrone, Fabiana [VerfasserIn] Favari, Elda [VerfasserIn] Maglietta, Giuseppe [VerfasserIn] Verzè, Michela [VerfasserIn] Pluchino, Monica [VerfasserIn] Minari, Roberta [VerfasserIn] Sabato, Roberto [VerfasserIn] Mazzaschi, Giulia [VerfasserIn] Ronca, Annalisa [VerfasserIn] Rossi, Alessandra [VerfasserIn] Cortellini, Alessio [VerfasserIn] Pecci, Federica [VerfasserIn] Cantini, Luca [VerfasserIn] Bersanelli, Melissa [VerfasserIn] Quaini, Federico [VerfasserIn] Tiseo, Marcello [VerfasserIn] Buti, Sebastiano [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.81$jOnkologie 44.45$jImmunologie
Themen:	ABCA1 ABCG1 Cholesterol efflux capacity Cholesterol loading capacity Immunotherapy Passive diffusion

RVK:	RVK Klassifikation ELIB24

Anmerkungen:	© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:	10.1007/s00262-023-03398-3

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC214383859X

Internformat


LEADER	01000naa a22002652 4500
001	OLC214383859X
003	DE-627
005	20240118092014.0
007	cr uuu---uuuuu
008	240118s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00262-023-03398-3 \|2 doi
035			\|a (DE-627)OLC214383859X
035			\|a (DE-He213)s00262-023-03398-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a ELIB24 \|q VZ \|2 rvk
084			\|a 44.81$jOnkologie \|2 bkl
084			\|a 44.45$jImmunologie \|2 bkl
100	1		\|a Perrone, Fabiana \|e verfasserin \|4 aut
245	1	0	\|a The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
520			\|a Introduction Immune checkpoint inhibitors (ICIs) became the standard of care for several solid tumors. A limited fraction of patients (pts) achieves a long-term benefit. Plasmatic and intracellular cholesterol levels have emerged as promising biomarkers. The aim of the present study was to determine whether cholesterol efflux capacity (CEC), mediated by serum transporters (ABCA1 and ABCG1) and passive diffusion (PD), impacts on clinical outcome of advanced non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) pts treated with ICIs. Material and methods We retrospectively enrolled advanced NSCLC and mRCC pts consecutively treated with ICIs between October 2013 and October 2018. CEC and cholesterol loading capacity (CLC) were assessed by well-established specific cell models. As primary endpoint, CEC, PD and CLC were correlated with overall survival (OS) while the effects of these parameters on progression-free survival (PFS) and clinical benefit (CB), defined as complete/partial response or stable disease, represented secondary endpoints. Results NSCLC accounted for 94.2% of 70 enrolled cases, and serum sample suitable for CEC and PD determination was available in 68. Blood cholesterol and serum ABCA1, ABCG1, PD and CLC were associated with outcomes (OS, PFS and CB) at univariate analysis. At the multivariate analysis, only PD confirmed its positive prognostic value in terms of OS, PFS and CB. Conclusion The favorable impact of cholesterol PD on clinical outcome might reflect its main conformation in mature HDL particles which potentially shape an inflamed context, ultimately promoting ICI efficacy. Further prospective studies are needed to support our findings and uncover targetable pathways.
650		4	\|a Cholesterol efflux capacity
650		4	\|a ABCA1
650		4	\|a ABCG1
650		4	\|a Passive diffusion
650		4	\|a Cholesterol loading capacity
650		4	\|a Immunotherapy
700	1		\|a Favari, Elda \|4 aut
700	1		\|a Maglietta, Giuseppe \|4 aut
700	1		\|a Verzè, Michela \|4 aut
700	1		\|a Pluchino, Monica \|4 aut
700	1		\|a Minari, Roberta \|4 aut
700	1		\|a Sabato, Roberto \|4 aut
700	1		\|a Mazzaschi, Giulia \|4 aut
700	1		\|a Ronca, Annalisa \|4 aut
700	1		\|a Rossi, Alessandra \|4 aut
700	1		\|a Cortellini, Alessio \|4 aut
700	1		\|a Pecci, Federica \|4 aut
700	1		\|a Cantini, Luca \|4 aut
700	1		\|a Bersanelli, Melissa \|4 aut
700	1		\|a Quaini, Federico \|4 aut
700	1		\|a Tiseo, Marcello \|4 aut
700	1		\|a Buti, Sebastiano \|4 aut
773	0	8	\|i Enthalten in \|t Cancer immunology immunotherapy \|d Springer Berlin Heidelberg, 1976 \|g 72(2023), 7 vom: 24. Feb., Seite 2127-2135 \|h Online-Ressource \|w (DE-627)253390443 \|w (DE-600)1458489-X \|w (DE-576)072283475 \|x 1432-0851 \|7 nnns
773	1	8	\|g volume:72 \|g year:2023 \|g number:7 \|g day:24 \|g month:02 \|g pages:2127-2135
856	4	0	\|u https://dx.doi.org/10.1007/s00262-023-03398-3 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2132
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
936	b	k	\|a 44.81$jOnkologie \|q VZ \|0 106409433 \|0 (DE-625)106409433
936	b	k	\|a 44.45$jImmunologie \|q VZ \|0 106409689 \|0 (DE-625)106409689
951			\|a AR
952			\|d 72 \|j 2023 \|e 7 \|b 24 \|c 02 \|h 2127-2135

The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände